Back to top

Image: Bigstock

Why Juno Therapeutics (JUNO) Could Be Positioned for a Slump

Read MoreHide Full Article

Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns. Selling off losers can be difficult, but if both the share price and estimates are falling, it could be time to get rid of the security before more losses hit your portfolio.

One such stock that you may want to consider dropping is Juno Therapeutics Inc. , which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year. A Zacks Rank #4 (Sell) further confirms weakness in JUNO.

Although for the current year JUNO has seen no estimate revision, the consensus estimate has trended lower, going from a loss of $2.37 a share a month ago to its current level of a loss of $2.67.

Similarly for the current quarter, the consensus estimate is down to a loss of 51 cents a share from a loss of 38 cents per share over the past 30 days.  

The stock also has seen some pretty dismal trading lately, as the share price has dropped 29.4% in the past month.

JUNO THERAPEUTC Price and Consensus

JUNO THERAPEUTC Price and Consensus | JUNO THERAPEUTC Quote

So it may not be a good decision to keep this stock in your portfolio anymore, at least if you don’t have a long time horizon to wait.

If you are still interested in the Medical-Biomedical/Genetics industry, you may instead consider a better-ranked stock - Enzo Biochem Inc. (ENZ - Free Report) . The stock currently holds a Zacks Rank #1 (Strong Buy) and may be a better selection at this time.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>


See More Zacks Research for These Tickers


Normally $25 each - click below to receive one report FREE:


Enzo Biochem, Inc. (ENZ) - free report >>

Published in